Caplin Point moves up on getting Colombia's INVIMA approval for Softgel Capsules division
Caplin Point Laboratories is currently trading at Rs. 1301.70, up by 2.90 points or 0.22% from its previous closing of Rs. 1298.80 on the BSE.
The scrip opened at Rs. 1300.00 and has touched a high and low of Rs. 1321.00 and Rs. 1277.85 respectively. So far 7824 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1617.80 on 19-Feb-2024 and a 52 week low of Rs. 673.10 on 05-May-2023.
Last one week high and low of the scrip stood at Rs. 1370.15 and Rs. 1277.85 respectively. The current market cap of the company is Rs. 9836.35 crore.
The promoters holding in the company stood at 70.62%, while Institutions and Non-Institutions held 4.43% and 24.95% respectively.
Caplin Point Laboratories has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3 and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).
The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
